Literature DB >> 6969775

Selective suppression of retroviral gp70-anti-gp70 immune complex formation by prostaglandin E1 in murine systemic lupus erythematosus.

S Izui, V E Kelley, P J McConahey, F J Dixon.   

Abstract

The effect of pharmacologic quantities of prostaglandin E1 (PGE) was investigated in three strains of mice (NZB X NZW, MRL/1, and BXSB) that spontaneously develop lupus-like glomerulonephritis. PGE-treatment prolonged survival and retarded the glomerular deposition of immune complex (IC) and the development of glomerulonephritis in NZB X NZW and MRL/1 mice, but did not similarly protect BXSB mice. Changes in the responsive strains correlated well with reduced amounts of circulating gp70 complexed with anti-gp70 antibodies compared with untreated controls, although total concentrations of gp70 (free and complexed) detectable in sera were similar in both groups of mice. The results strongly suggest that: (a) PGE selectively suppressed the immune response to retroviral gp70, (b) PGe had little effect on the quantity or quality of anti-DNA antibodies but did reduce the deposition of anti-DNA containing IC in the kidneys, and (c) gp70 IC appear to play an important role in the pathogenesis of glomerulonephritis in murine systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6969775      PMCID: PMC2186019          DOI: 10.1084/jem.152.6.1645

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  Estimation of the double-helical content in various single-stranded nucleic acids by treatment with a single strand-specific nuclease.

Authors:  K Shishido; T Ando
Journal:  Biochim Biophys Acta       Date:  1972-12-22

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Structural proteins of oncogenic ribonucleic acid viruses. Interspec II, a new interspecies antigen.

Authors:  M Strand; J T August
Journal:  J Biol Chem       Date:  1973-08-25       Impact factor: 5.157

4.  Reactions of staphylococcal antigens with normal sera, gamma G-globulins, and gamma G-globulin fragments of various species origin.

Authors:  A Grov; P Oeding; B Myklestad; J Aasen
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1970

5.  Iodination of nucleic acids in vitro.

Authors:  S L Commerford
Journal:  Biochemistry       Date:  1971-05-25       Impact factor: 3.162

6.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

7.  Modification of NZB-NZW F1 autoimmune disease by development of tolerance to DNA.

Authors:  L P Parker; B H Hahn; C K Osterland
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

8.  DNA:anti-DNA complexes: their detection in systemic lupus erythematosus sera.

Authors:  R J Harbeck; E J Bardana; P F Kohler; R I Carr
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

9.  Pathogenesis of the glomerulonephritis of NZB/W mice.

Authors:  P H Lambert; F J Dixon
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

10.  The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice.

Authors:  T Yoshiki; R C Mellors; M Strand; J T August
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

View more
  20 in total

Review 1.  The lupus-prone BXSB strain: the Yaa gene model of systemic lupus erythematosus.

Authors:  R Merino; L Fossati; S Izui
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Mechanism of prostaglandin E2 inhibition of acute changes in vascular permeability.

Authors:  K R McLeish; S R Wellhausen; G T Stelzer
Journal:  Inflammation       Date:  1987-09       Impact factor: 4.092

3.  Sgp3 and Sgp4 control expression of distinct and restricted sets of xenotropic retroviruses encoding serum gp70 implicated in murine lupus nephritis.

Authors:  Masao Kihara; Valérie Leroy; Lucie Baudino; Leonard H Evans; Shozo Izui
Journal:  J Autoimmun       Date:  2011-10-07       Impact factor: 7.094

4.  Prostaglandin E1 suppresses macrophage infiltration and ameliorates injury in an experimental model of macrophage-dependent glomerulonephritis.

Authors:  V Cattell; J Smith; H T Cook
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

5.  Enzyme-linked immunosorbent assay for detection of retroviral gp70 and gp70-anti-gp70 immune complexes in sera from SLE mice.

Authors:  S Izui; G Lange
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

Review 6.  Autoimmune diseases: immunopathology and etiopathogenesis.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1982-09       Impact factor: 4.307

Review 7.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

8.  Dissection of genetic mechanisms governing the expression of serum retroviral gp70 implicated in murine lupus nephritis.

Authors:  Lucie Baudino; Kumiko Yoshinobu; Naoki Morito; Shuichi Kikuchi; Liliane Fossati-Jimack; Bernard J Morley; Timothy J Vyse; Sachiko Hirose; Trine N Jørgensen; Rebecca M Tucker; Christina L Roark; Brian L Kotzin; Leonard H Evans; Shozo Izui
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

9.  Association of elevated serum glycoprotein gp70 with increased gp70 immune complex formation and accelerated lupus nephritis in autoimmune male BXSB mice.

Authors:  S Izui; I Hara; L M Hang; J H Elder; P J McConahey; F J Dixon
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

10.  Murine lupus nephritis: effects of cyclophosphamide on circulating and tissue bound immunoreactants.

Authors:  T Cavallo; K Graves; N A Granholm
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.